BioAffinity Technologies Sees Accelerating Growth Of Physician Practices Ordering CyPath Lung Tests
BioAffinity Technologies Sees Accelerating Growth Of Physician Practices Ordering CyPath Lung Tests
BioAffinity Technologies看到醫生處方CyPath肺部檢測的增長加速
Sales of CyPath Lung tests, onboarding of pathology practices ahead of forecasts
CyPath肺部檢查的銷售，病理診所的入職時間超出預期
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, today reported 139% growth in the number of pulmonology practices and physicians offering CyPath Lung to patients since Jan. 1, 2024. CyPath Lung is a noninvasive test to detect early-stage lung cancer.
生物技術公司BioAffinity Technologies, Inc.（納斯達克股票代碼：BIAF，BIAFW））是一家專注於早期癌症和肺部疾病檢測需求的生物技術公司，今天報告稱，自2024年1月1日以來，向患者提供CyPath Lung的肺科診所和醫生數量增長了139％。CyPath 肺是一種無創性測試，用於檢測早期肺癌。